Exceptional Response’ to First-Line Vismodegib Reported in Patient With Unresectable/Multifocal Adult Medulloblastoma

Wednesday, January 18, 2017 - 3:30pm

brainThe ASCO Post highlighted the extraordinary response to targeted therapy of a patient with an adult medulloblastoma brain tumor, the first such report in the first-line setting using hedgehog inhibitor vismodegib (Erivedge).  The case report was published in Cancer Biology & Therapy, by Emil Lou, Assistant Professor of Medicine, University of Minnesota.  The patient is doing well and is cancer-free several years later.